Skin Appendage Disorders最新文献

{"title":"Efficacy of Heterologous Type I Collagen Injections in Treating Atrophic Acne Scars: A Prospective Study.","authors":"Aikaterini Gkouvi, Aikaterini Tsiogka, Andrea Corbo, Antonios Tsimpidakis, Stamatios Gregoriou","doi":"10.1159/000544166","DOIUrl":"https://doi.org/10.1159/000544166","url":null,"abstract":"<p><strong>Introduction: </strong>Treatment of acne scars includes laser therapies, microneedling, chemical peels, and dermal fillers. Herein, we sought to assess the efficacy and safety of heterologous type I collagen injections (HT1Cs) on atrophic acne scars.</p><p><strong>Methods: </strong>One hundred milligrams of HT1C were injected beneath each atrophic acne scar on patients with atrophic acne scars graded as 2, 3, or 4 according to the Goodman and Baron's acne scar grading system. Patients underwent four treatment sessions at 2-week intervals, and they were evaluated for up to week 52, using the above-mentioned grading system and a 0-10 visual analogue scale (VAS).</p><p><strong>Results: </strong>30 patients (9 males: 21 females; median [range] age 32 [18-50] years) were enrolled in the study. At baseline, 10 (33%), 17 (57%), and 3 (10%) patients presented with grade 2, 3, and 4 scaring. At 3-month follow-up, 7 (23%), 16 (53%), 4 (13%), and 3 (10%) of patients presented with grade 1, 2, 3, and 4 scaring, respectively. At the same visit, physicians rated the mean improvement as 6.8, while patients rated it slightly higher at 7.2. The observed improvements were sustained up to 12 months. The mean patients' satisfaction rate at 3 months was 7.4. No major adverse events were reported throughout the entire duration of the follow-up period.</p><p><strong>Conclusion: </strong>The results of the present study highlight the efficacy, sustainability, and safety of HT1C injections in treating atrophic acne scars.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":"11 4","pages":"316-319"},"PeriodicalIF":1.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12324723/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144795486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased Prevalence of Antinuclear Antibody Positivity in Central Centrifugal Cicatricial Alopecia Patients.","authors":"Michael M Ong, Amit Singal, Shari R Lipner","doi":"10.1159/000543767","DOIUrl":"https://doi.org/10.1159/000543767","url":null,"abstract":"<p><strong>Introduction: </strong>Central centrifugal cicatricial alopecia (CCCA) is a primary scarring alopecia predominantly affecting black women. Autoimmune mechanisms, including antinuclear antibody (ANA) positivity, have been hypothesized to contribute to its pathogenesis but remain underexplored.</p><p><strong>Method: </strong>Using the TriNetX database (2004-2024), we identified black women with CCCA and controls with other primary scarring alopecias. Patients were propensity score matched by current age and age at diagnosis. We compared the prevalence of ANA positivity and autoimmune comorbidities before and after alopecia diagnosis. Statistical significance was defined as an adjusted <i>p</i> value <0.05.</p><p><strong>Results: </strong>Among 5,811 CCCA patients and matched controls, CCCA patients were more likely to have positive ANA (11.8% vs. 2.0%, <i>p</i> < 0.001) and systemic lupus erythematosus (SLE) post-diagnosis (0.9% vs. 0.3%, <i>p</i> = 0.007). They were less likely to have type 1 diabetes pre-diagnosis (2.9% vs. 4.8%, <i>p</i> = 0.007) and post-diagnosis (0.8% vs. 1.3%, <i>p</i> = 0.024). No significant differences were found in other autoimmune diseases.</p><p><strong>Conclusion: </strong>CCCA patients had higher prevalence of ANA positivity and SLE, supporting potential autoimmune involvement. However, screening for other autoimmune diseases in asymptomatic CCCA patients may not be necessary. Further research is needed to clarify the interplay between autoimmune and metabolic pathways in CCCA.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":"11 4","pages":"385-388"},"PeriodicalIF":1.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12324734/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144795499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Upadacitinib for Alopecia: Current Evidence and Clinical Insights.","authors":"Thomas Stirrat, Sach Thakker, Deeptha Bejugam, Carolyn Goh, Shari R Lipner","doi":"10.1159/000544868","DOIUrl":"https://doi.org/10.1159/000544868","url":null,"abstract":"<p><strong>Background: </strong>Upadacitinib, a selective Janus kinase (JAK) 1 inhibitor, has demonstrated promising efficacy in alopecia areata (AA), particularly in patients unresponsive to conventional therapies. As JAK inhibitors gain prominence, understanding upadacitinib's role in AA management is critical.</p><p><strong>Summary: </strong>This scoping review synthesizes data from 24 publications, including 64 AA patients treated with upadacitinib (15-45 mg daily). Most patients experience substantial or complete hair regrowth within 1-4 months. The most common AA subtypes include alopecia universalis (<i>n</i> = 28), ophiasis (<i>n</i> = 15), and alopecia totalis (<i>n</i> = 8). Upadacitinib was generally well tolerated, with mild adverse events such as transient acneiform eruptions, leukopenia, and creatine phosphokinase elevations. Many patients with comorbid autoimmune conditions, such as atopic dermatitis (59.4%) and inflammatory bowel disease, also reported improvement. Despite these promising findings, limitations include small cohort sizes, variability in prior treatments, and reliance on case reports. Two ongoing studies are underway: a US Phase 3 clinical trial (M23-716) assessing long-term efficacy and safety, and a real-world observational study in China (NCT06573593) comparing upadacitinib with other JAK inhibitors. These studies underscore the need for larger, controlled trials to establish standardized treatment protocols and long-term safety outcomes.</p><p><strong>Key messages: </strong>(i) Upadacitinib demonstrates good efficacy in treating AA. (ii) Its safety profile supports potential off-label use. (iii) Larger studies are essential to validate current findings and optimize management.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":"11 4","pages":"320-334"},"PeriodicalIF":1.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12324716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144795504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eyebrow Microblading: Science, Art, and Complications.","authors":"Mansak Shishak, Madhu Kuthial","doi":"10.1159/000543753","DOIUrl":"https://doi.org/10.1159/000543753","url":null,"abstract":"<p><strong>Background: </strong>Eyebrows are a distinct facial feature and any shift in their appearance impacts self-perception of external beauty attributes. There may be loss of hairs, or changes in pigment and texture due to primary or secondary causes.</p><p><strong>Summary: </strong>A surge in demand for microblading in recent years, majorly for aesthetic value, has driven curiosity and requests for the procedure. This has translated to subjective dissatisfaction with cosmetic outcomes while also increasing the risk of complications and immunogenically driven adverse events.</p><p><strong>Key messages: </strong>Understanding the nuances of the technique and undertaking basic precautions will enable safe and desirable results in this common procedure.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":"11 4","pages":"355-359"},"PeriodicalIF":1.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12324725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144795487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Scarring Alopecia Therapies from the Patient Perspective: Knowledge, Barriers to Care, and Treatment Satisfaction.","authors":"Anna Brinks, Caitlin Kearney, Carli Needle, Akshay Pulavarty, Jerry Shapiro, Kristen I Lo Sicco","doi":"10.1159/000547557","DOIUrl":"10.1159/000547557","url":null,"abstract":"<p><strong>Introduction: </strong>Scarring alopecias (SAs) cause permanent hair loss and psychological distress. With no FDA-approved SA treatments, patients face significant barriers to care. Despite promising evidence supporting the use of Janus kinase inhibitors (JAKi) to treat SAs, access remains limited. This study aimed to assess the demographic profile, psychosocial burden, treatment experiences, and barriers to care among patients with SA.</p><p><strong>Methods: </strong>An IRB-approved online survey was distributed to adults (≥18 years) with a self-reported SA diagnosis via the Scarring Alopecia Foundation (SAF) listserv and at the April 2025 SAF Conference. Wilcoxon-Mann-Whitney U tests and χ² tests were performed using SAS v9.4.</p><p><strong>Results: </strong>Among 294 respondents (98.0% female, mean age 61, 81.3% White), common diagnoses included frontal fibrosing alopecia (66.3%), lichen planopilaris (41.5%), and central centrifugal cicatricial alopecia (12.6%). Only 37.5% reported well-controlled symptoms; 78.9% experienced SA-related depression or anxiety. JAKi awareness was high (71%), but use was low (30%), with significant differences based on gender, region, income, and education. Barriers to treatment access included provider reluctance (46%), insurance denial (18%), and high cost (16%).</p><p><strong>Conclusions: </strong>SA patients face significant psychosocial distress and barriers to accessing therapies. Improving equitable access to care requires enhanced provider education, broader insurance coverage, and stronger patient assistance programs.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503516/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric Pityriasis Amiantacea: A Multicenter Retrospective Study of 76 Patients.","authors":"Felipe Tavares Rodrigues, Rita Fernanda Cortez de Almeida, Luciana Rodino Lemes, Carla Jorge Machado, Bianca Maria Piraccini, Michela Starace, Luca Rapparini, Nino Lortkipanidze, Asmahanane Souissi, Sineida Berbert Ferreira, Luna Azulay-Abulafia, Taynara Barreto, Regina Lúcia Barbosa Santos, Antonella Tosti, Colombina Vincenzi, Daniel Asz Sigall, Sebastian Agusto Mercau, Andrei Doroshkevich, Tatiana Silyuk, Luis Enrique Sánchez-Dueñas, Gabriel Lazzeri Cortez, Isabella Doche, Claudia Montoya, Daniela Gutiérrez-Mendoza, Sergio Vaño-Galván, Hudson Dutra Rezende, Verena Florenço, Daniela Guzman-Sanchez, Alejandro Bonifaz, Daniel Fernandes Melo","doi":"10.1159/000547530","DOIUrl":"10.1159/000547530","url":null,"abstract":"<p><strong>Introduction: </strong>Pityriasis amiantacea (PA), also known as pseudotinea amiantacea, is a scalp disorder characterized by adherent scales surrounding hair tufts, with an unclear etiopathogenesis potentially linked to inflammatory scalp diseases such as psoriasis, seborrheic dermatitis, and atopic dermatitis.</p><p><strong>Methods: </strong>This retrospective multicenter study analyzed the epidemiology, clinical presentation, trichoscopic features, and management of 76 pediatric patients diagnosed with PA across 22 centers.</p><p><strong>Results: </strong>Pruritus was the hallmark symptom, and scarring alopecia was rare in pediatric patients. Regarding trichoscopy, recognizing the vascular patterns is demonstrated to be valuable for severe or unresponsive cases. In our study, monotherapy using topical steroid treatment generally led to favorable outcomes, suggesting that PA may be less aggressive in children due to earlier diagnosis and less severe inflammation.</p><p><strong>Conclusion: </strong>This study highlights the importance of recognizing PA in pruritic scalp conditions in pediatric patients, suggesting effective management strategies that can improve quality of life despite the psychosocial impact of the disease.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Onychotillomania Dentata: A Newly Defined Oral-Induced Pattern of Repetitive Nail Trauma.","authors":"Eduardo Corona-Rodarte, Juan Jimenez-Cauhe, Michela Starace, Matilde Iorizzo, Germán Juanicotena-Madrigal, Bianca Maria Piraccini, Brian Morrison, Daniel Asz-Sigall","doi":"10.1159/000547308","DOIUrl":"10.1159/000547308","url":null,"abstract":"<p><strong>Introduction: </strong>Onychotillomania is a body-focused repetitive behavior disorder characterized by compulsive trauma to the nail unit. While manual manipulation is well recognized, oral-induced mechanisms remain undocumented. We describe a novel subset involving frictional trauma from the teeth, which we term onychotillomania dentata.</p><p><strong>Case presentation: </strong>An 11-year-old female presented with a 1-year history of progressive thumbnail dystrophy. Clinical history revealed a habitual behavior occurring predominantly at night: inserting the thumbs into the mouth and rubbing the nail plates against the lower incisors in a repetitive anteroposterior motion. The patient described the behavior as soothing and unconscious. Signs of concomitant onychophagia were also present. Examination demonstrated central nail plate concavity, lamellar splitting, periungual erythema, and localized subungual hyperkeratosis. Dermoscopy revealed lamellar onychoschizia, linear furrows, and compact subungual debris. Behavioral counseling was initiated, including thumb guards during sleep and positive reinforcement strategies. Oral n-acetylcysteine (600 mg every 12 h) was prescribed as adjunctive therapy. Referral to pediatric psychodermatology was recommended for behavioral assessment and initiation of habit-reversal training.</p><p><strong>Conclusion: </strong>Onychotillomania dentata represents a previously undescribed pattern of nail trauma within the broader spectrum of onychotillomania. While classical onychotillomania typically results from manual manipulation, onychotillomania dentata is distinguished by repetitive oro-digital friction. Clinical features include central concavity, lamellar splitting, and linear furrows along the axis of mechanical trauma. Diagnosis often relies heavily on clinical morphology and dermoscopy, especially as many patients may deny their behavioral habit. Early recognition is crucial to avoid misdiagnosis and unnecessary treatment. Additionally, chronic mechanical friction may pose a risk of dental damage, including enamel erosion. Management involves behavioral modification strategies, pharmacologic support when appropriate, and interdisciplinary psychodermatologic care.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503714/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dutasteride Infusion in Male Androgenetic Alopecia Using a Novel Drug Delivery Technique: MMP^®.","authors":"Luciana Gasques, Alice Lima, Mariana Lima, Antonella Tosti, Marcio Silva, Marina Barletta","doi":"10.1159/000546871","DOIUrl":"10.1159/000546871","url":null,"abstract":"<p><strong>Introduction: </strong>MMP® (the Portuguese acronym for microinfusão de medicamentos na pele [i.e., microinfusion of drugs into the skin]) is a novel drug delivery technique that uses microneedling to infuse drugs into the skin. Scalp microinfusion is a promising intervention for hair loss.</p><p><strong>Aim: </strong>The aim of the study was to evaluate the efficacy and safety of microinfusion of dutasteride with the MMP® technique compared with microinfusion of saline solution (placebo) in men with androgenetic alopecia (AGA). This is the first study that compared microinfusion with MMP® using dutasteride versus placebo for the treatment of AGA.</p><p><strong>Methods: </strong>A prospective, multicenter, controlled clinical trial was conducted in eight (8) adult male patients with AGA. Three applications of dutasteride or placebo (saline solution 0.9%) using the MMP® were made every 30 days. Photos pre- and posttreatment were analyzed by three blinded dermatologists and the patient. Efficacy and safety were evaluated.</p><p><strong>Results: </strong>No statistical difference in the clinical assessment was found between the groups. However, patient self-assessment reported marked improvement in the vertex area in the dutasteride group.</p><p><strong>Conclusion: </strong>Dutasteride microinfusion using the MMP® technique is effective in treating male AGA. Microneedling with MMP® without any medication is effective in treating male AGA.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic Onychodystrophy Revealing Amelanotic Nail Unit Melanoma in a Moroccan Patient: A Case Report.","authors":"Bouchra Baghad, Fouzia Hali, Yousra Habibi, Fatima Anejjar, Bahija Lemrhari, Bouchra Mouaouya, Meriem Regragui, Mounia Diouri, Soumiya Chiheb","doi":"10.1159/000546886","DOIUrl":"10.1159/000546886","url":null,"abstract":"<p><strong>Introduction: </strong>Nail unit melanoma is a rare and potentially aggressive variant of acral lentiginous melanoma. Diagnosing amelanotic variants can be particularly challenging due to the absence of typical pigmentation. Here, we report a case of chronic onychodystrophy revealing amelanotic nail unit melanoma.</p><p><strong>Case presentation: </strong>A 48-year-old Moroccan patient presented with chronic persistent monodactylic nail dystrophy. Dermoscopy showed subungual hyperkeratosis with an atypical vascular pattern but no pigmented structures. A biopsy of the nail unit confirmed amelanotic melanoma. Staging (PET scan, lymph node ultrasound, and bone CT) excluded metastases. Surgical management led to metacarpophalangeal amputation of the thumb.</p><p><strong>Conclusion: </strong>This case underscores the need to consider amelanotic melanoma in patients with atypical or persistent nail lesions. Early recognition and prompt treatment can significantly affect prognosis. Monodactylous involvement with nail dystrophy, including nail plate destruction, should lead to a nail biopsy for an early and accurate diagnosis.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical Treatment of Digital Mucous Cysts with Autografting of the Overlying Skin: A Retrospective Observational Study of 29 Cases.","authors":"Nilton Gioia Di Chiacchio, Nilton Di Chiacchio, Jorge Ocampo-Gaza, Leandro Fonseca Noriega, Lucas de Araújo Freire Santos","doi":"10.1159/000547018","DOIUrl":"10.1159/000547018","url":null,"abstract":"<p><strong>Introduction: </strong>Digital mucous cysts (DMCs) are benign lesions commonly involving the distal interphalangeal joint and proximal nail folds. Although recurrence is common, surgical excision remains the most effective treatment. This study assessed the recurrence rate of DMCs following surgical excision with autografting of the overlying skin.</p><p><strong>Methods: </strong>This was a retrospective, observational, and descriptive study based on photographic and medical record review of 29 patients treated between 2008 and 2024, with a minimum follow-up of 6 months and a mean follow-up of 74.4 months. The surgical procedure involved excision of the DMC, autografting of the overlying skin, and application of Brown's dressing for 10 days to ensure sustained local pressure. Recurrence was defined as clinical reappearance of the cyst.</p><p><strong>Results: </strong>The cohort had a mean age of 61 years, with 89.7% being female. The recurrence rate was 6.9% (2/29), with both recurrences occurring early (at 3 and 10 months). Notably, no recurrences were observed in toe lesions, despite their high proportion (12/29 cases).</p><p><strong>Conclusion: </strong>Surgical excision followed by autografting of the overlying skin and application of Brown's dressing resulted in a low recurrence rate. Sustained local pressure appears to promote fibrosis, contributing to long-term cyst resolution.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12263159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144650520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}